New compound reduces alpha synuclein by 97%

[rhenry45]

ir.prothena.com/releasedeta...

This is a very interesting technology.

[Catlou]

yeah!

[BUZZ1397]

Yay for the Irish

[silvestrov]

Here is a review with more details than the posted article and it also contains information about other prospective therapies:

alanhobbes.blogspot.com/201...

[p-oui in reply to silvestrov]

good link, thanks

[silvestrov]

I don't want to be a 'buzz kill', (buzz kill being defined as some schmuck who gives negative information that decreases hope thus lowering dopamine levels). But I have (being a dopamine lowering buzz kill) to note that monoclonal antibodies are expensive and have side effects. First a good article about their cost:

Monoclonal antibodies: Magic bullets with a hefty price tag

researchgate.net/publicatio...

Secondly, SIDE EFFECTS, if you have ever watched a Humira commercial you will hear similar things for the new drug... If you have an infection.......

rxlist.com/script/main/mobi...

[parkie13 in reply to silvestrov]

perfect, that's what big pharma wants

[rhenry45 in reply to silvestrov]

It may have some side effects but so does Sinemet. It looks like you would only need to use it a few times to get 97% clearance of the alpha synuclein. I think this may be a good solution.

[silvestrov in reply to rhenry45]

There are plenty of substances which can dissolve alpha synuclein and they cost much less than this proposed drug. From the article about monoclonal antibodies and ' hefty price tag':

$200 000: average cost of treating a patient for a year with one of the top nine biologicals in the US

I have controlled parkinsonism without any evidence of dementia and am not in need of this drug. Having said that I do take 'nootropic' supplements which improve cognition and have shown clinical evidence of destroying lewy bodies: NAC, black tea extract, alpha lipoic acid & acetyl l carnitine, EGCG, magnesium, bacalin/baicalein. And there are others...the point is there is no money in producting natural supplements by drug companies. I have more faith in Chinese and Indian scientists than I do in major drug companies.

[Serenity_finaly-1 in reply to silvestrov]

Is there a way for you to be both an Artist and perhaps a nature path specialising in PD. I am astounded by how sharp your mind is. When I was diagnosed Parkinson's it was a movement disorder so I went out to beat it. I have found the physical aspects is so much easier to deal with than the more mental aspects..

[silvestrov in reply to Serenity_finaly-1]

Previously I completed 9 1/2 years of full time college and am disinclined to go back for more. Prior to earning my 2 art degrees I completed a bachelors was in business management. Rather than going back to school I just compulsively read about various aspects on the subject of PD. I am happy my intellectual wandering contributes to the welfare of others on this site.

[Serenity_finaly-1 in reply to silvestrov]

So do you kick butt when watching Jeopardy?

[park_bear in reply to silvestrov]

It's not at all clear that monoclonal Abs are the right tool for the job. From what I can discern from the literature it appears nilotinib actually corrects the defective signaling. A less toxic version that did the same thing would be a big advance, and nilotinib is not expensive to produce.

[silvestrov in reply to park_bear]

A monoclonal antibody therapy is being developed to reduce inflammation for Rheumatoid arthritis and Parkinson's disease as caused by Toll-like receptor 2 (Tlr-2). And TLR-2 has very much been implicated in PD:

Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology

ncbi.nlm.nih.gov/pmc/articl...

Development of Anti-toll-like Receptor (TLR)-2 Monoclonal Antibody as a Therapeutic Agent in Parkinson's Disease

michaeljfox.org/foundation/...

Yes monoclonal antibodies are expensive and possibly dangerous, but it will be interesting to see the study results from the above MA. As for Nilotinib, will it show the same promise and bust in clinical trials like GDNF?

Interestingly both Prothena and Opsona are both Irish companies.

[rhenry45 in reply to silvestrov]

I want to see a compound that sweeps out all of the defective alpha synuclien